

Capital Markets Day Epidemiology

December 10, 2019



Agenda

Immunology	
Vaccines	
Rare Diseases	Jac
Multiple Sclerosis / Neurology	
Rare Blood Disorders	
Oncology	Ę

Dupixent[®]: Atopic Dermatitis Adult 18+

8,174 7,136 Prevalence 1,416 16,726 Treated 5,722 5.231 1,038 11,991 Of which 595 6,230 2,638 2,997 moderate-to-severe 1.675 1.121 3.018 Moderate-to-Severe uncontrolled **Biologics eligible** 222 189 Treated with multiple systemic steroids or one Most in need 301 590 immunosuppressant or phototherapy⁽²⁾ +100 5,000 10.000 15.000 0 US Japan EU5⁽¹⁾



Dupixent[®]: Atopic Dermatitis Adolescents 12-17yo

2,497 2,538 5,035 Prevalence Treated 2.072 2.297 4,369 Of which 1,015 1,792 777 moderate-to-severe Moderate-to-Severe uncontrolled **Biologics eligible** 734 389 345 Treated with multiple systemic steroids or one Most in need 166 258 immunosuppressant or phototherapy⁽²⁾ - 92 1.000 2.000 3.000 4.000 5,000 0 US EU5⁽¹⁾



Dupixent[®]: Atopic Dermatitis Child 6-11yo


Prevalence 2,457 2,853 5,310 Treated 1,985 2,305 4,290 Of which 1,612 718 894 moderate-to-severe Assuming eligibility limited to severe uncontrolled Biologics eligible 162 in pediatric indications 2,000 4,000 0 US EU5⁽¹⁾

2018 number of patients (thousands)

SANOFI Source: Sanofi analysis (1) Germany, France, Italy, Spain & United Kingdom


Dupixent[®]: Atopic Dermatitis Child <6yo

2018 number of patients (thousands)



SANOFI Source: Sanofi analysis (1) Germany, France, Italy, Spain & United Kingdom

Dupixent®: Asthma 12+




2018 number of patients (thousands)

Source: Sanofi analysis


SANOFI 🎝


ICS: Inhaled Corticosteroids; OCS: Oral Corticosteroids (1) Germany, France, Italy, Spain & United Kingdom (2) For EU, severe with persistent use of ICS or OCS (3) For EU, severe uncontrolled or OCS dependent

Dupixent[®]: Asthma 6-11yo




Dupixent®: Eosinophilic Esophagitis 12+





Dupixent[®]: Chronic Rhinosinusitis with Nasal Polyposis

2018 number of patients (thousands)






Source: Sanofi analysis
(1) Germany, France, Italy, Spain & United Kingdom
(2) For EU, patients with severe CRSwNP inadequately controlled on systemic corticosteroids and / or surgery


Dupixent[®]: Bullous Pemphigoid 18+

2018 number of patients (thousands)





SANOFI SOURCE: Sanofi analysis OCS: Oral Corticosteroids (1) Germany, France, Italy, Spain & United Kingdom

Dupixent[®]: Prurigo Nodularis 12+



Dupixent®: Chronic Spontaneous Urticaria





SANOFI Source: Sanofi analysis

Dupixent[®]: Chronic Obstructive Pulmonary Disease

Prevalence 10,052 10.753 22,889 2,084 Treated 8.367 8.700 1.473 18.540 GOLD D 1,222 207 3,010 1.581 COPD with Type 2 phenotype uncontrolled with current SoC (patients that are on triple therapy Type 2 population 550 300 among GOLD D) 50 2,000 0 10,000 18.000 20.000 22,000 US Japan EU5⁽¹⁾

2018 number of patients (thousands)




Source: Sanofi analysis SoC: Standard of Care; GOLD criteria: Global Initiative for Chronic Obstructive Lung Disease - Group D: high risk (≥2 exacerbations / year, or one+ requiring hospitalization) and more symptoms (mMRC≥ 2 or CAT≥ 10) (1) Germany, France, Italy, Spain & United Kingdom

Agenda

Immunology	
Vaccines	
Rare Diseases	JA.
Multiple Sclerosis / Neurology	\bigcirc
Rare Blood Disorders	
Oncology	Ę

Nirsevimab: RSV



2020e number of births (thousands)




Source: US Census Bureau Population Division; EU Eurostat; National Institute of Population and Social Security Research; World Bank (1) Germany, France, Italy, Spain & United Kingdom

Agenda

Immunology	
Vaccines	
Rare Diseases	T
Multiple Sclerosis / Neurology	
Rare Blood Disorders	
Oncology	Ę

Venglustat: Gaucher Disease Type 3




Source: Sanofi analysis
(1) All Europe
(2) Numbers shown represent individual patient counts

SANOFI 🗸

Venglustat: GM2 gangliosidoses

2018 number of patients⁽²⁾



GM2 gangliosidoses: Rare (1) All Europe


SANOFI 🎝

GM2 gangliosidoses: Rare autosomal recessive genetic disorders including Tay-Sachs and Sandhoff disease


(1) All Europe(2) Numbers shown represent individual patient counts

Venglustat: Fabry Disease

2018 number of patients⁽²⁾





Venglustat: ADPKD





Avalglucosidase alfa: Pompe Disease






Source: Sanofi analysis IOPD: Infantile Onset Pompe Disease (1) All Europe (2) Numbers shown represent individual patient counts

SANOFI 🗸

Olipudase alfa: Acid Sphingomyelinase Deficiency

2018 number of patients⁽²⁾




Source: Sanofi analysis (1) All Europe (2) Numbers shown represent individual patient counts

SANOFI 🗸

miRNA21: Alport Syndrome

2018 estimated number of patients⁽²⁾




SANOFI 🎝

Agenda


Immunology	
Vaccines	
Rare Diseases	T
Multiple Sclerosis / Neurology	\bigcirc
Multiple Sclerosis / Neurology Rare Blood Disorders	

MS: Primary Progressive Multiple Sclerosis



MS: Non-Relapsing Secondary Progressive MS


2018 number of patients (thousands)






Source: Sanofi analysis MS: Multiple Sclerosis; DMT: Disease Modifying Therapy (1) Germany, France, Italy, Spain & United Kingdom


MS: Relapsing Forms of Multiple Sclerosis





Venglustat: GBA-PD

2018 number of patients (thousands)





Source: Sanofi analysis GBA-PD: Glucocerebrosidase Mutations in Parkinson Disease Total Diagnosed PD population: 3.1M (U.S.: 1.1M; EU5: 1.4M; Japan: 0.6M) (1) Germany, France, Italy, Spain & United Kingdom

Agenda


Immunology	
Vaccines	
Rare Diseases	The second secon
Multiple Sclerosis / Neurology	\bigcirc
Rare Blood Disorders	
Oncology	Ę

Fitusiran & BIVV001: Hemophilia A

Non-inhibitor moderate & 8.3 9.1 3.7 21.1 severe treated, 12+ years Non-inhibitor moderate & 2.8 1.5 0.6 **4.9** severe treated, <12 years 1.1 0.1 Inhibitor patients⁽²⁾ 1.9 5 10 15 20 25 0 US Japan EU5⁽¹⁾



Fitusiran: Hemophilia B




2018 number of patients (thousands)

SANOFI Source: Sanofi analysis (1) Germany, France, Italy, Spain & United Kingdom

Sutimlimab: Cold Agglutinin Disease


2018 number of patients (thousands)





Source: Berentsen S, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica. 2006;91(4):460-466; Sanofi analysis (1) Germany, France, Italy, Spain & United Kingdom

Sutimlimab: Immune Thrombocytopenia






Agenda

Immunology	
Vaccines	
Rare Diseases	JA.
Multiple Sclerosis / Neurology	\bigcirc
Rare Blood Disorders	
Oncology	Ę

SERD: HR+/HER2- Breast Cancer



2018 number of eligible treated patients⁽²⁾ (thousands)



Source: Kantar Health, 2018 figures (1) Germany, France, Italy, Spain & United Kingdom (2) Includes pre- & post-menopausal patients

Sarclisa®: Multiple Myeloma


13.7 1L Ti 14.2 3.3 31.1 1L Te 11.6 9.7 2.3 23.6 2L 16.5 14.3 3.4 34.3 3L+ 19.0 12.9 3.1 35.0 Smoldering 1.2 2.4 0.2 10 20 0 30 40 US EU5⁽¹⁾ Japan

2018 number of treated patients (thousands)



Source: Decision Resources Group, 2019; Sanofi analysis Ti: Transplant ineligible; Te: Transplant eligible (1) Germany, France, Italy, Spain & United Kingdom


Libtayo®: Cutaneous Squamous Cell Carcinoma



2018 number of patients (thousands)

SANOFI Source: Sanofi analysis (1) Germany, France, Italy, Spain & United Kingdom

Libtayo®: Non-Small-Cell Lung Carcinoma




(1) Germany, France, Italy, Spain & United Kingdom

SANOFI 🗸

(2) Includes squamous and non-squamous

Anti-CEACAM5: Non-Small-Cell Lung Carcinoma

2018 number of patients (thousands)



SANOFI 🎝


Libtayo[®]: Basal Cell Carcinoma


1L - Diagnosed Includes metastatic and locally advanced patients 1.2 0.9 2.0 incidence not candidates for curative surgery or radiation 1L - Patients treated 0.9 0.6 1.5 with systemic therapy 2L - Patients treated 0.8 0.6 1.3 with systemic therapy 0.0 0.5 1.0 1.5 2.0 2.5 EU5⁽¹⁾ US

2018 number of patients (thousands)

SANOFI Source: Sanofi analysis (1) Germany, France, Italy, Spain & United Kingdom

Libtayo[®]: Cervical Cancer





Capital Markets Day Epidemiology

December 10, 2019



For further information please contact:

Investor Relations Paris Tel: +33 1 53 77 45 45 Bridgewater Tel: +1 908 981 5560 Email: IR@sanofi.com

> Media Relations Tel: +33 1 53 77 46 46 Email: MR@sanofi.com

<u>www.sanofi.com</u> 54, rue de la Boétie – 75008 Paris - FRANCE

